P90 ribosomal S6 kinases : A bona fide target for novel targeted anticancer therapies?
(2023) In Biochemical Pharmacology 210.- Abstract
The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have... (More)
The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, function, and mechanisms associated with carcinogenesis. We additionally present and discuss the recent advances but also the limitations in the development of pharmacological inhibitors of RSKs, in the context of the use of these kinases as putative, more efficient targets for novel anticancer therapeutic approaches.
(Less)
- author
- Koutsougianni, Fani ; Alexopoulou, Dimitra ; Uvez, Ayca ; Lamprianidou, Andromachi ; Sereti, Evangelia LU ; Tsimplouli, Chrisiida ; Ilkay Armutak, Elif and Dimas, Konstantinos
- organization
- publishing date
- 2023-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cancer, Inhibitors, P90 ribosomal s6 kinases, Signaling, Targeted therapy
- in
- Biochemical Pharmacology
- volume
- 210
- article number
- 115488
- publisher
- Elsevier
- external identifiers
-
- scopus:85149893072
- pmid:36889445
- ISSN
- 0006-2952
- DOI
- 10.1016/j.bcp.2023.115488
- language
- English
- LU publication?
- yes
- id
- 0f70ad6d-274b-454b-9b8d-9591caed6bfb
- date added to LUP
- 2023-04-24 13:47:41
- date last changed
- 2024-09-21 11:14:46
@article{0f70ad6d-274b-454b-9b8d-9591caed6bfb, abstract = {{<p>The 90 kDa ribosomal S6 kinase (RSK) family of proteins is a group of highly conserved Ser/Thr kinases. They are downstream effectors of the Ras/ERK/MAPK signaling cascade. ERK1/2 activation directly results in the phosphorylation of RSKs, which further, through interaction with a variety of different downstream substrates, activate various signaling events. In this context, they have been shown to mediate diverse cellular processes like cell survival, growth, proliferation, EMT, invasion, and metastasis. Interestingly, increased expression of RSKs has also been demonstrated in various cancers, such as breast, prostate, and lung cancer. This review aims to present the most recent advances in the field of RSK signaling that have occurred, such as biological insights, function, and mechanisms associated with carcinogenesis. We additionally present and discuss the recent advances but also the limitations in the development of pharmacological inhibitors of RSKs, in the context of the use of these kinases as putative, more efficient targets for novel anticancer therapeutic approaches.</p>}}, author = {{Koutsougianni, Fani and Alexopoulou, Dimitra and Uvez, Ayca and Lamprianidou, Andromachi and Sereti, Evangelia and Tsimplouli, Chrisiida and Ilkay Armutak, Elif and Dimas, Konstantinos}}, issn = {{0006-2952}}, keywords = {{Cancer; Inhibitors; P90 ribosomal s6 kinases; Signaling; Targeted therapy}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Biochemical Pharmacology}}, title = {{P90 ribosomal S6 kinases : A bona fide target for novel targeted anticancer therapies?}}, url = {{http://dx.doi.org/10.1016/j.bcp.2023.115488}}, doi = {{10.1016/j.bcp.2023.115488}}, volume = {{210}}, year = {{2023}}, }